APO Research
Talk to an analyst

APO RESEARCH · REPORT

Calcitonin Gene Related Peptide Type 1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Calcitonin Gene Related Peptide Type 1 Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchCalcitonin Gene Related Peptide Type 1 Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Calcitonin Gene Related Peptide Type 1 Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Calcitonin Gene Related Peptide Type 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Calcitonin Gene Related Peptide Type 1 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Calcitonin Gene Related Peptide Type 1 Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Calcitonin Gene Related Peptide Type 1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Calcitonin Gene Related Peptide Type 1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Calcitonin Gene Related Peptide Type 1 market include Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Amgen Inc, Vertex Pharmaceuticals Inc, Merck & Co Inc, Fortress Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Calcitonin Gene Related Peptide Type 1 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Calcitonin Gene Related Peptide Type 1 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Calcitonin Gene Related Peptide Type 1 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Calcitonin Gene Related Peptide Type 1 market size, projected growth trends, production technologies, key applications, and end-use industries.

Calcitonin Gene Related Peptide Type 1 Segment by Company

Teva Pharmaceutical Industries Ltd

Eli Lilly and Company

Amgen Inc

Vertex Pharmaceuticals Inc

Merck & Co Inc

Fortress Biotech Inc

Biohaven Pharmaceutical Holding Company Ltd

Allergan Plc

Calcitonin Gene Related Peptide Type 1 Segment by Type

Erenumab

CGRP

AGN-241689

AFAP-3

Others

Calcitonin Gene Related Peptide Type 1 Segment by Application

Dental Pain

Cardiovascular

Metabolic Disorders

Others

Calcitonin Gene Related Peptide Type 1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Calcitonin Gene Related Peptide Type 1 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Calcitonin Gene Related Peptide Type 1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Calcitonin Gene Related Peptide Type 1 significant trends, drivers, influence factors in global and regions.

6. To analyze Calcitonin Gene Related Peptide Type 1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Calcitonin Gene Related Peptide Type 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Calcitonin Gene Related Peptide Type 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Calcitonin Gene Related Peptide Type 1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Calcitonin Gene Related Peptide Type 1 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Calcitonin Gene Related Peptide Type 1 industry.

Chapter 3: Detailed analysis of Calcitonin Gene Related Peptide Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Calcitonin Gene Related Peptide Type 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Calcitonin Gene Related Peptide Type 1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Calcitonin Gene Related Peptide Type 1 Industry Trends Table 2. Calcitonin Gene Related Peptide Type 1 Industry Drivers Table 3. Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges Table 4. Calcitonin Gene Related Peptide Type 1 Industry Restraints Table 5. Global Calcitonin Gene Related Peptide Type 1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Calcitonin Gene Related Peptide Type 1 Revenue Share by Company (2021-2026) Table 7. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Company (k units) & (2021-2026) Table 8. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Company (2021-2026) Table 9. Global Calcitonin Gene Related Peptide Type 1 Average Price (US$/unit) of Company (2021-2026) Table 10. Global Calcitonin Gene Related Peptide Type 1 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Calcitonin Gene Related Peptide Type 1 Key Company Manufacturing Base & Headquarters Table 12. Global Calcitonin Gene Related Peptide Type 1 Company, Product Type & Application Table 13. Global Calcitonin Gene Related Peptide Type 1 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Calcitonin Gene Related Peptide Type 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Erenumab Table 18. Significant Companies of CGRP Table 19. Significant Companies of AGN-241689 Table 20. Significant Companies of AFAP-3 Table 21. Significant Companies of Others Table 22. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type (2021-2026) & (k units) Table 24. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type (2027-2032) & (k units) Table 25. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Type (2021-2026) Table 26. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Type (2027-2032) Table 27. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type (2021-2026) Table 31. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Dental Pain Table 33. Significant Companies of Cardiovascular Table 34. Significant Companies of Metabolic Disorders Table 35. Significant Companies of Others Table 36. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application (2021-2026) & (k units) Table 38. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application (2027-2032) & (k units) Table 39. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Application (2021-2026) Table 40. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Application (2027-2032) Table 41. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application (2021-2026) Table 45. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application (2027-2032) Table 46. Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2026) & (k units) Table 48. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region (2021-2026) Table 49. Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2027-2032) & (k units) Table 50. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region (2027-2032) Table 51. Global Calcitonin Gene Related Peptide Type 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Region (2021-2026) Table 54. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Region (2027-2032) Table 56. Global Calcitonin Gene Related Peptide Type 1 Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Calcitonin Gene Related Peptide Type 1 Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Calcitonin Gene Related Peptide Type 1 Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 61. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2026) Table 62. Global Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 63. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2027-2032) Table 64. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Calcitonin Gene Related Peptide Type 1 Sales Value Market Share by Country (2021-2026) Table 66. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Calcitonin Gene Related Peptide Type 1 Sales Value Market Share by Country (2027-2032) Table 68. Teva Pharmaceutical Industries Ltd Company Information Table 69. Teva Pharmaceutical Industries Ltd Business Overview Table 70. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 72. Teva Pharmaceutical Industries Ltd Recent Development Table 73. Eli Lilly and Company Company Information Table 74. Eli Lilly and Company Business Overview Table 75. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 77. Eli Lilly and Company Recent Development Table 78. Amgen Inc Company Information Table 79. Amgen Inc Business Overview Table 80. Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 82. Amgen Inc Recent Development Table 83. Vertex Pharmaceuticals Inc Company Information Table 84. Vertex Pharmaceuticals Inc Business Overview Table 85. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 87. Vertex Pharmaceuticals Inc Recent Development Table 88. Merck & Co Inc Company Information Table 89. Merck & Co Inc Business Overview Table 90. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 92. Merck & Co Inc Recent Development Table 93. Fortress Biotech Inc Company Information Table 94. Fortress Biotech Inc Business Overview Table 95. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 97. Fortress Biotech Inc Recent Development Table 98. Biohaven Pharmaceutical Holding Company Ltd Company Information Table 99. Biohaven Pharmaceutical Holding Company Ltd Business Overview Table 100. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 102. Biohaven Pharmaceutical Holding Company Ltd Recent Development Table 103. Allergan Plc Company Information Table 104. Allergan Plc Business Overview Table 105. Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 107. Allergan Plc Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Calcitonin Gene Related Peptide Type 1 Distributors List Table 111. Calcitonin Gene Related Peptide Type 1 Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Calcitonin Gene Related Peptide Type 1 Product Image Figure 2. Global Calcitonin Gene Related Peptide Type 1 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Calcitonin Gene Related Peptide Type 1 Sales (2021-2032) & (k units) Figure 5. Global Calcitonin Gene Related Peptide Type 1 Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Calcitonin Gene Related Peptide Type 1 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Erenumab Image Figure 10. CGRP Image Figure 11. AGN-241689 Image Figure 12. AFAP-3 Image Figure 13. Others Image Figure 14. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Type (2021-2032) Figure 17. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type (2021-2032) Figure 20. Dental Pain Image Figure 21. Cardiovascular Image Figure 22. Metabolic Disorders Image Figure 23. Others Image Figure 24. Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Application (2021-2032) Figure 27. Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application (2021-2032) Figure 30. Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Calcitonin Gene Related Peptide Type 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 35. North America Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 41. South America Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Calcitonin Gene Related Peptide Type 1 Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Calcitonin Gene Related Peptide Type 1 Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Erenumab
  • CGRP
  • AGN-241689
  • AFAP-3
  • Others
Applications
  • Dental Pain
  • Cardiovascular
  • Metabolic Disorders
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Eli Lilly and Company
  • Amgen Inc
  • Vertex Pharmaceuticals Inc
  • Merck & Co Inc
  • Fortress Biotech Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  4. 1.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales Volume (2021-2032)
  5. 1.2.3 Global Calcitonin Gene Related Peptide Type 1 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Calcitonin Gene Related Peptide Type 1 Market Dynamics
  1. 2.1 Calcitonin Gene Related Peptide Type 1 Industry Trends
  2. 2.2 Calcitonin Gene Related Peptide Type 1 Industry Drivers
  3. 2.3 Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges
  4. 2.4 Calcitonin Gene Related Peptide Type 1 Industry Restraints
3 Calcitonin Gene Related Peptide Type 1 Market by Company
  1. 3.1 Global Calcitonin Gene Related Peptide Type 1 Company Revenue Ranking in 2025
  2. 3.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Company (2021-2026)
  3. 3.3 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Company (2021-2026)
  4. 3.4 Global Calcitonin Gene Related Peptide Type 1 Average Price by Company (2021-2026)
  5. 3.5 Global Calcitonin Gene Related Peptide Type 1 Company Ranking (2024-2026)
  6. 3.6 Global Calcitonin Gene Related Peptide Type 1 Company Manufacturing Base and Headquarters
  7. 3.7 Global Calcitonin Gene Related Peptide Type 1 Company Product Type and Application
  8. 3.8 Global Calcitonin Gene Related Peptide Type 1 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Calcitonin Gene Related Peptide Type 1 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Calcitonin Gene Related Peptide Type 1 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Calcitonin Gene Related Peptide Type 1 Market by Type
  1. 4.1 Calcitonin Gene Related Peptide Type 1 Type Introduction
  2. 4.1.1 Erenumab
  3. 4.1.2 CGRP
  4. 4.1.3 AGN-241689
  5. 4.1.4 AFAP-3
  6. 4.1.5 Others
  7. 4.2 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type
  8. 4.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type
  12. 4.3.1 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type (2021-2032)
5 Calcitonin Gene Related Peptide Type 1 Market by Application
  1. 5.1 Calcitonin Gene Related Peptide Type 1 Application Introduction
  2. 5.1.1 Dental Pain
  3. 5.1.2 Cardiovascular
  4. 5.1.3 Metabolic Disorders
  5. 5.1.4 Others
  6. 5.2 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application
  7. 5.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Calcitonin Gene Related Peptide Type 1 Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application
  11. 5.3.1 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Application (2021-2032)
  13. 5.3.3 Global Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application (2021-2032)
6 Calcitonin Gene Related Peptide Type 1 Regional Sales and Value Analysis
  1. 6.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2032)
  3. 6.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021-2026
  4. 6.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2027-2032)
  5. 6.3 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Region (2027-2032)
  9. 6.5 Global Calcitonin Gene Related Peptide Type 1 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  12. 6.6.2 North America Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  15. 6.7.2 Europe Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  21. 6.9.2 South America Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Calcitonin Gene Related Peptide Type 1 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Calcitonin Gene Related Peptide Type 1 Sales Value Share by Country, 2025 VS 2032
7 Calcitonin Gene Related Peptide Type 1 Country-level Sales and Value Analysis
  1. 7.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  4. 7.3.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026)
  5. 7.3.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032)
  6. 7.4 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Calcitonin Gene Related Peptide Type 1 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Calcitonin Gene Related Peptide Type 1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Amgen Inc
  14. 8.3.1 Amgen Inc Company Information
  15. 8.3.2 Amgen Inc Business Overview
  16. 8.3.3 Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  18. 8.3.5 Amgen Inc Recent Developments
  19. 8.4 Vertex Pharmaceuticals Inc
  20. 8.4.1 Vertex Pharmaceuticals Inc Company Information
  21. 8.4.2 Vertex Pharmaceuticals Inc Business Overview
  22. 8.4.3 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  24. 8.4.5 Vertex Pharmaceuticals Inc Recent Developments
  25. 8.5 Merck & Co Inc
  26. 8.5.1 Merck & Co Inc Company Information
  27. 8.5.2 Merck & Co Inc Business Overview
  28. 8.5.3 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  30. 8.5.5 Merck & Co Inc Recent Developments
  31. 8.6 Fortress Biotech Inc
  32. 8.6.1 Fortress Biotech Inc Company Information
  33. 8.6.2 Fortress Biotech Inc Business Overview
  34. 8.6.3 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  36. 8.6.5 Fortress Biotech Inc Recent Developments
  37. 8.7 Biohaven Pharmaceutical Holding Company Ltd
  38. 8.7.1 Biohaven Pharmaceutical Holding Company Ltd Company Information
  39. 8.7.2 Biohaven Pharmaceutical Holding Company Ltd Business Overview
  40. 8.7.3 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  42. 8.7.5 Biohaven Pharmaceutical Holding Company Ltd Recent Developments
  43. 8.8 Allergan Plc
  44. 8.8.1 Allergan Plc Company Information
  45. 8.8.2 Allergan Plc Business Overview
  46. 8.8.3 Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  48. 8.8.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Calcitonin Gene Related Peptide Type 1 Value Chain Analysis
  2. 9.1.1 Calcitonin Gene Related Peptide Type 1 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Calcitonin Gene Related Peptide Type 1 Sales Mode & Process
  6. 9.2 Calcitonin Gene Related Peptide Type 1 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Calcitonin Gene Related Peptide Type 1 Distributors
  9. 9.2.3 Calcitonin Gene Related Peptide Type 1 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst